Intestinal Energy Crisis Triggers Systemic Aging in Gut-Liver Axis

A Specific Intestinal Energy Crisis Triggers Systemic Aging

Aging does not affect all tissues equally. Research led by Li Y and colleagues at the Tianjin Institute of Industrial Biotechnology shows the intestine enters a specific, preventable energy crisis that damages distant organs. Their study, published in Aging Cell, identifies a breakdown in the gut-liver axis starting with intestinal mitochondria.

Mitochondrial Failure and HDL3 Deficiency in the Aging Gut

With age, cells in the intestinal lining experience a decline in mitochondrial oxidative phosphorylation. This is more than just general wear and tear. It creates a local ATP deficit severe enough to impair a protein called ABCA1, responsible for transporting lipids to form a specific type of high-density lipoprotein, HDL3. The study found that aging intestines produce dramatically less HDL3, not due to a lack of raw materials, but because the cellular energy required for its assembly is missing.

“This is a direct path from mitochondrial dysfunction to a specific deficiency with systemic consequences,” explained Xue J, a co-author on the paper. The gut-derived HDL3 is not the same as liver-produced HDL associated with cardiovascular health. Instead, it serves a distinct protective role.

Gut-Derived HDL3 Neutralizes Liver Inflammation

The team discovered that HDL3 synthesized in the intestine travels to the liver via the portal circulation. Its primary function there is to bind and neutralize bacterial lipopolysaccharide (LPS), a pro-inflammatory toxin that can leak through a weakened intestinal barrier. In young, healthy systems, gut-derived HDL3 acts as a molecular sponge, preventing LPS from triggering the TLR4 inflammatory pathway in liver cells. The aging-related collapse of intestinal HDL3 production removes this protective layer, leading to chronic liver inflammation and injury.

β-Nicotinamide Mononucleotide (NMN) Restores the Axis

The researchers tested whether addressing the root cause—the intestinal energy deficit—could reverse this cascade. They administered the NAD+ precursor NMN to aged mice.

NMN Repletes NAD+, Rescues Mitochondria, and Restores HDL3

Supplementation restored intestinal NAD+ levels. This, in turn, enhanced the efficiency of mitochondrial oxidative phosphorylation, increasing ATP production. With sufficient cellular energy restored, the ABCA1 transporter functioned correctly, and the biosynthesis of intestinal HDL3 was rejuvenated to youthful levels. Consequently, LPS neutralization in the liver resumed, TLR4-mediated inflammation was attenuated, and age-related liver injury improved. The study maps a clear pathway: NMN modulates the NAD+-mitochondria-ABCA1-HDL3 axis to preserve gut-liver homeostasis. A detailed breakdown of this mechanism is available in our article, Restoring Gut-Liver Axis: NMN Targets Aging Intestinal Energy.

The Human Evidence for NAD+ Supplementation: Strong Biochemistry, Mixed Functional Results

While rodent studies like the one from Tianjin present compelling mechanistic stories, the translation to human health outcomes is complex. A 2026 systematic review by Gallagher C and Emmanuel OO in Ageing Research Reviews examined 113 eligible preclinical and clinical studies on NAD+ augmentation from 2010 to 2025.

Biochemical Efficacy is Clear

The review confirmed that oral NAD+ precursors, primarily nicotinamide riboside (NR) and NMN, reliably engage their biochemical target. “In humans, oral NR and NMN consistently demonstrated biochemical target engagement,” the authors wrote, noting increases in circulating and cellular NAD+ metabolites across studies. These supplements are generally well-tolerated over periods of weeks to months.

Healthspan Outcomes Remain Heterogeneous

The effects on measurable human health, however, are inconsistent. The review found that “effects on functional, metabolic, vascular, and other healthspan-relevant outcomes were heterogeneous and often null or endpoint-specific.” Some trials report improvements in vascular flexibility or muscle metabolism, while others show no significant change compared to placebo. The authors identified no rigorous outcomes trials for intravenous NAD+ administration for anti-aging purposes, highlighting a significant evidence gap in the wellness clinic setting.

Integrating NMN into a Broader Healthspan Strategy

The science indicates NMN is a tool with a defined molecular mechanism, not a universal panacea. Its potential utility depends on context and combination.

Who Might Benefit Most?

Based on the current evidence, individuals with indications of metabolic aging, such as declining mitochondrial function or specific issues related to gut-barrier integrity and liver inflammation, might be more likely to experience a functional benefit. The robust biochemical data suggests supplementation reliably boosts NAD+ levels, which decline with age in everyone. Our comprehensive guide to NMN supplementation details the current evidence landscape.

NMN is Not a Standalone Solution

Mitochondrial health depends on multiple factors. The energy crisis in the aging gut described by Li Y’s team is one facet of a system-wide process. Effective healthspan protocols combine nutritional strategies like caloric restriction with physical activity, which directly preserves aging muscle mitochondrial health. Senolytic compounds like dasatinib and quercetin target a different hallmark of aging—cellular senescence. NMN may support one fundamental pillar; a comprehensive approach addresses several.

Practical Considerations and the State of Research

Dosage, timing, and form are active areas of investigation. Most human NMN studies use doses between 250mg and 1000mg daily. Preclinical research often employs much higher equivalent doses, making direct comparison difficult. The choice between NMN and NR may come down to bioavailability and personal response, as both effectively raise NAD+.

It is critical to acknowledge the limitations. The 2026 systematic review clearly states that long-term human safety data is still being gathered, and proof of clinical benefit for aging is not yet conclusive. The field lacks large, multi-year trials measuring hard healthspan endpoints like disability prevention or disease incidence.

Key Takeaways

• Aging intestines undergo a specific mitochondrial energy crisis that halts production of protective HDL3, leading to liver inflammation.
• Exogenous NMN supplementation can reverse this gut-liver axis failure in mice by restoring NAD+ levels, mitochondrial ATP production, and HDL3 synthesis.
• Human trials consistently show oral NMN and NR boost NAD+ metabolites, demonstrating clear biochemical efficacy.
• Evidence for functional improvements in human healthspan from NAD+ supplementation is mixed, with studies reporting heterogeneous results on metabolic and vascular endpoints.
• No rigorous trials support intravenous NAD+ for anti-aging, and long-term human safety data for all forms is still evolving.
• NMN should be considered a potential component within a broader, evidence-based healthspan strategy that includes diet, exercise, and other interventions.
• Individual response is variable, and consultation with a healthcare provider familiar with longevity science is advised before beginning supplementation.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41851037/
https://pubmed.ncbi.nlm.nih.gov/41655607/
https://pubmed.ncbi.nlm.nih.gov/41512967/

This article is for informational purposes only. Consult a qualified professional for personalised advice.